ProQR Therapeutics

About

ProQR Therapeutics is a biotech company focused on developments of drugs to treat genetic disorders.

Leiden,Zuid-Holland,The Netherlands
101 - 250
https://www.proqr.com/

Highlights

Details

Last Funding Type: Post-IPO Equity
Industries: Biotechnology,Genetics,Health Care,Therapeutics
Founded date: Jan 1, 2012
Number Of Employee: 101 - 250
Operating Status: Active
Stock Symbol: nasdaq:PRQR
Legal Name: ProQR Therapeutics NV

ProQR Therapeutics is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. The company's main product candidates are QR-010, QR-110, and QR-313. Its product pipeline includes QRX-704, QRX-504, QRX-421, QRX-323 etc.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

9

$392.60M €46.70M

ProQR Therapeutics has raised a total of $392.60M €46.70M in funding over 2 rounds. Their latest funding was raised on Dec 26, 2022 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Dec 26, 2022	Post-IPO Equity	—	1	Eli Lilly	—	Detail
Mar 30, 2021	Post-IPO Equity	$103.50M	—	—	—	Detail
Jul 14, 2020	Post-IPO Debt	$30M	1	Pontifax	—	Detail
Oct 15, 2019	Post-IPO Equity	$57.50M	—	—	—	Detail
Dec 10, 2018	Post-IPO Debt	€4.70M	—	—	—	Detail